MBX Biosciences (MBX) Cash from Investing Activities (2023 - 2026)

MBX Biosciences has reported Cash from Investing Activities for 4 years, with the latest figure at -$97.1 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 3109.83% year-over-year to -$97.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$184.0 million (down 6.5% YoY) and the FY2025 annual result came in at -$83.7 million, up 47.88% from the prior year.
• Cash from Investing Activities grew to -$97.1 million in Q1 2026 per MBX's latest filing, from -$130.0 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $26.0 million in Q2 2025 and troughed at -$130.0 million in Q4 2025.
• A 4-year average of -$37.0 million and a median of -$18.4 million in 2023 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2025 and 2026: Cash from Investing Activities surged 429.31% in 2025, then sank 3109.83% in 2026.
• Over 4 years, Cash from Investing Activities stood at -$29.0 million in 2023, then sank by 132.59% to -$67.3 million in 2024, then slumped by 93.0% to -$130.0 million in 2025, then gained by 25.29% to -$97.1 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$97.1 million, -$130.0 million, and $17.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.